{"entity":{"id":"nct05703971","kind":"trial","name":"Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients","aka":["Acclaim-3"],"tldr":"A phase 1/2 trial of Atezolizumab in small-cell lung cancer, run by Genprex, Inc., now recruiting.","summary":"Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients is a phase 1/2 interventional study registered as NCT05703971 by Genprex, Inc., with 62 participants planned, started 2024-05-09 and due to reach its primary completion in 2027-12. Interventions recorded: quaratusugene ozeplasmid, atezolizumab. Conditions listed: Small Cell Lung Cancer Extensive Stage. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05703971","url":"https://clinicaltrials.gov/study/NCT05703971"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc","extensive-stage-sclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["atezolizumab"],"companies":["genprex"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05703971","phase":"1/2","setting":"A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)","sponsor":"Genprex, Inc.","participation":[{"nct":"NCT05703971","source":"https://clinicaltrials.gov/study/NCT05703971","fetchedAt":"2026-10-07T16:53:52.193Z","studySha256":"443472be21631f4569f1afe3e60ac74fae7ee24ea8247d3bc114f06d58a5d9da","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-11","leadSponsor":"Genprex, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":62,"enrolmentType":"ESTIMATED","siteCount":17,"recruitingSiteCount":16,"countries":["United States"]}],"started":"2024-05-09","startedType":"actual","enrolled":62,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05703971/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"}],"company":[{"id":"genprex","kind":"company","name":"Genprex","route":"/companies/genprex/"}]}}